Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Admune Therapeutics

M&A STATUS
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of pharmaceutical and biotechnology services. The company provide medical consultancy, cytokine cancer therapies and cancer-immuno therapy.

Website
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Primary Office
  • 107 Water Street
  • Danvers, MA 01923
  • United States

Admune Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Admune Therapeutics‘s full profile, request access.

Request full access to PitchBook

Admune Therapeutics Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BeiGene Formerly PE-Backed Beijing, China 0000 00.000 00000000 00.000
00000000 000000000 Formerly PE-Backed Suzhou, China 000 00000 00000000 00000
0000 0000000000 Venture Capital-Backed Beijing, China 000.00 00000000000 000.00
0000000 00000000 0 Venture Capital-Backed Beijing, China 0000 00000000000 0000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
To view this company’s complete list of competitors, request access »

Admune Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Sergio Finkielsztein President & Chief Executive Officer